{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:50:53Z","timestamp":1790351453379,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"16","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T00:00:00Z","timestamp":1724112000000},"content-version":"vor","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012669","name":"Natural Science Foundation Project of Chongqing","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012669","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.heliyon.2024.e36640","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T05:54:45Z","timestamp":1724392485000},"page":"e36640","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pharmaceutical inhibition of BCL6 ameliorates resistance to imatinib in chronic myeloid leukemia"],"prefix":"10.1016","volume":"10","author":[{"given":"Yingying","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.heliyon.2024.e36640_bib1","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1182\/blood.V98.6.1732","article-title":"Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia","volume":"98","author":"Huntly","year":"2001","journal-title":"Blood"},{"issue":"5405","key":"10.1016\/j.heliyon.2024.e36640_bib2","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: a new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.heliyon.2024.e36640_bib3","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1056\/NEJMoa040258","article-title":"Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML","volume":"351","author":"Jamieson","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e36640_bib4","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1002\/cncr.26679","article-title":"Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy","volume":"118","author":"Huang","year":"2012","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e36640_bib5","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/blood-2009-06-227017","article-title":"The integrated biochemical and computational approach identifies BCL6 direct target genes controlling multiple pathways in normal germinal center B cells","volume":"115","author":"Basso","year":"2010","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e36640_bib6","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.molmed.2014.03.001","article-title":"Breaking bad in the germinal center: how deregulation of BCL6 contributes to lymphomagenesis","volume":"20","author":"Hatzi","year":"2014","journal-title":"Trends Mol. Med."},{"issue":"22","key":"10.1016\/j.heliyon.2024.e36640_bib7","doi-asserted-by":"crossref","first-page":"5536","DOI":"10.1182\/blood-2008-12-193037","article-title":"The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL","volume":"113","author":"Ci","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e36640_bib8","doi-asserted-by":"crossref","DOI":"10.1172\/JCI133090","article-title":"BCL6 confers KRAS-mutant non-small-cell lung cancer resistance to BET inhibitors","volume":"131","author":"Guo","year":"2021","journal-title":"J. Clin. Investig."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e36640_bib9","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/sj.bjc.6605010","article-title":"BCL6 degradation caused by the interaction with the C-terminus of pro-HB-EGF induces cyclin D2 expression in gastric cancers","volume":"100","author":"Hirata","year":"2009","journal-title":"Br. J. Cancer"},{"issue":"36","key":"10.1016\/j.heliyon.2024.e36640_bib10","doi-asserted-by":"crossref","first-page":"5572","DOI":"10.1038\/sj.onc.1206689","article-title":"BCL-6 is expressed in breast cancer and prevents mammary epithelial differentiation","volume":"22","author":"Logarajah","year":"2003","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e36640_bib11","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0092-8674(00)80595-4","article-title":"Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor","volume":"96","author":"Brunet","year":"1999","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e36640_bib12","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood.2019001745","article-title":"BCL6 maintains the survival and self-renewal of primary human acute myeloid leukemia cells","volume":"137","author":"Kawabata","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e36640_bib13","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12967-016-0859-z","article-title":"ERK1\/2, MEK1\/2, and p38 downstream signaling molecules impaired in CD56 dim CD16+ and CD56 bright CD16 dim\/- natural killer cells in Chronic Fatigue Syndrome\/Myalgic Encephalomyelitis patients","volume":"14","author":"Huth","year":"2016","journal-title":"J. Transl. Med."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e36640_bib14","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1177\/0963689717720296","article-title":"ERK and p38 upregulation versus Bcl-6 downregulation in Rat kidney epithelial cells exposed to prolonged hypoxia","volume":"26","author":"Luo","year":"2017","journal-title":"Cell Transplant."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e36640_bib15","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc3317","article-title":"Pushing the limits of targeted therapy in chronic myeloid leukemia","volume":"12","author":"O'Hare","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.heliyon.2024.e36640_bib16","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0065-2776(10)05007-8","article-title":"BCL6: master regulator of the germinal center reaction and key oncogene in B cell lymphomagenesis","volume":"105","author":"Basso Kdalla-Favera","year":"2010","journal-title":"Adv. Immunol."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e36640_bib17","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1084\/jem.20110304","article-title":"BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia","volume":"208","author":"Hurtz","year":"2011","journal-title":"J. Exp. Med."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e36640_bib18","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1016\/j.celrep.2017.08.081","article-title":"Chemically induced degradation of the oncogenic transcription factor BCL6","volume":"20","author":"Kerres","year":"2017","journal-title":"Cell Rep."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e36640_bib19","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1172\/JCI85795","article-title":"Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma","volume":"126","author":"Cardenas","year":"2016","journal-title":"J. Clin. Investig."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e36640_bib20","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/nrm2938","article-title":"Heat shock factors: integrators of cell stress, development and lifespan","volume":"11","author":"Akerfelt","year":"2010","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e36640_bib21","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1517\/14728220902832697","article-title":"Inhibiting the transcription factor HSF1 as an anticancer strategy","volume":"13","author":"Whitesell","year":"2009","journal-title":"Expert Opin. Ther. Targets"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e36640_bib22","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.cell.2007.07.020","article-title":"Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis","volume":"130","author":"Dai","year":"2007","journal-title":"Cell"},{"issue":"13","key":"10.1016\/j.heliyon.2024.e36640_bib23","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1158\/0008-5472.CAN-11-0127","article-title":"Overcoming trastuzumab resistance in breast cancer by targeting dysregulated glucose metabolism","volume":"71","author":"Zhao","year":"2011","journal-title":"Cancer Res."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024126710?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024126710?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T22:46:01Z","timestamp":1773182761000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024126710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":23,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S2405844024126710"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e36640","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmaceutical inhibition of BCL6 ameliorates resistance to imatinib in chronic myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e36640","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e36640"}}